Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/1b Dose Escalation, Multicenter, Open-label, Safety, Pharmacokinetic and Pharmacodynamic Study of FT-1101 as a Single Agent and in Combination With Azacitidine in Patients With Relapsed or Refractory Hematologic Malignancies

NCT02543879 is registered in ClinicalTrials.gov with Forma Therapeutics, Inc. as lead sponsor.

NCT NCT02543879
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02543879 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/1b Dose Escalation, Multicenter, Open-label, Safety, Pharmacokinetic and Pharmacodynamic Study of FT-1101 as a Single Agent and in Combination With Azacitidine in Patients With Relapsed or Refractory Hematologic Malignancies
Lead sponsor
Forma Therapeutics, Inc.
Phase
Phase 1
Overall status
Completed
Start date
September 30, 2015
Completion date
March 31, 2019
Enrollment
94 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

acute myelogenous leukemia, acute myeloid leukemia, myelodysplastic syndrome, non-hodgkin lymphoma